A prior single-time-point (24 h) analysis in LNCaP xenograft–bearing mice showed 177Lu-rhPSMA-10.1 to have one of the lowest kidney uptakes of several evaluated PSMA-targeted radiopharmaceuticals, including 177Lu-PSMA-I&T and 177Lu-PSMA-617, while also preserving high tumor uptake (15). This evidence concerns the gene FOLH1 and neoplasm.